Findings
atherosclerotic cardiovascular disease, death, stroke
BLEEDING, MYOCARDIAL INFARCTION, STROKE, SECONDARY, ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
In this post hoc secondary analysis of 10 678 participants with atherosclerotic cardiovascular disease from the ADAPTABLE randomized clinical trial, there were no significant differences in the primary effectiveness (death, hospitalization for myocardial infarction, or hospitalization for stroke) or safety (major bleeding) end points between enteric-coated aspirin and uncoated aspirin among participants, regardless of which dose of aspirin they were assigned.